Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Initiates Phase 3 of Batoclimab in gMG in China


Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner Harbour BioMed has commenced the first dosing of Phase 3 of batoclimab in patients with generalized myasthenia gravis (gMG)​ in China.


For more information, please refer to the link below. 

- HBM press release link: